Quick answer: taking cagrilintide with retatrutide has not been studied in people, and neither has cagrilintide with tirzepatide. The only human combination data for cagrilintide are with semaglutide, as CagriSema.[3] A 2026 study found the cagrilintide-retatrutide pairing worked better than either drug alone in obese rats, but that is not evidence of safety or dosing in humans.[2] Neither cagrilintide nor retatrutide is FDA-approved, and FDA says neither can be used in compounding.[1]

For each drug on its own, see the cagrilintide profile and retatrutide profile.

Why people want to combine them

Cagrilintide is a long-acting copy of amylin, a fullness hormone. Retatrutide and tirzepatide are incretin drugs: tirzepatide acts on GIP and GLP-1 receptors, and retatrutide on those plus the glucagon receptor.[6] Amylin and incretin drugs reduce appetite through partly different pathways, so pairing them could add weight loss.

That idea has worked once in people. In REDEFINE 1, cagrilintide plus semaglutide lowered weight by 20.4% at 68 weeks, versus 11.5% for cagrilintide alone and 14.9% for semaglutide alone.[5] Searches for “cagrilintide with retatrutide” or “with tirzepatide” assume the same logic carries over to a stronger partner drug. It may or may not; no one has tested it.

What the 2026 rat study found

Researchers at the University of Copenhagen gave diet-induced obese male rats daily retatrutide, cagrilintide, or both.[2]

  • The combination reduced body weight and food intake in a dose-dependent way, more than equal doses of either drug alone.
  • It also beat matched-dose combinations of cagrilintide with semaglutide or with tirzepatide.
  • Cholesterol, triglycerides and insulin levels improved.
  • The extra weight loss could not be explained by eating less alone.

The authors described their results as preclinical and said they support developing future single molecules that act on several receptors.[2] Rats were dosed daily, not weekly, and only males were studied. Doses that work in rats do not translate directly to people.

How CagriSema was tested before it reached people

The route CagriSema took shows what a new combination normally needs before large trials:

  1. A phase 1b safety study. In 95 adults, cagrilintide doses from 0.16 to 4.5 mg were added to semaglutide 2.4 mg, with both raised every 4 weeks over 16 weeks. Researchers checked that cagrilintide did not change semaglutide levels in the blood.[14]
  2. Dose-finding trials of cagrilintide alone, which tested 0.3 to 4.5 mg weekly.[4]
  3. Large phase 3 trials of the chosen 2.4/2.4 mg dose.[3]

Both drugs are long-acting. Cagrilintide’s half-life was 159 to 195 hours in that phase 1b trial,[14] and retatrutide’s is about 6 days.[17] If a combination caused problems, they would not wear off quickly after the last injection.

No equivalent work exists for cagrilintide with retatrutide or tirzepatide, so the right dose, the interaction between the drugs and the side-effect rate are all unknown.

Cagrilintide with tirzepatide

No human study has combined cagrilintide with tirzepatide. The two were compared head to head instead: in REDEFINE 4, tirzepatide 15 mg produced 23.6% weight loss at 84 weeks versus 20.2% for CagriSema.[15] See CagriSema vs Zepbound.

Companies are testing amylin-plus-incretin pairings with their own drugs:

  • Lilly completed a phase 1 study of its amylin drug eloralintide given with tirzepatide in 188 people with overweight or obesity, and is running a phase 3 trial of eloralintide in about 900 people already on a weekly incretin.[12][13]
  • Novo Nordisk is testing cagrilintide with a long-acting GIP agonist (not tirzepatide) to study stomach tolerability.[11]

These trials show the idea is taken seriously. They also show that each specific pairing gets its own safety study first.

Risks of combining them

These are the risks that would be expected from what each drug does alone. None has been measured for the combination.

  • Stomach side effects. Cagrilintide alone caused nausea in 20% to 47% of people depending on dose.[4] CagriSema caused stomach side effects in 79.6%.[3] Retatrutide 12 mg caused nausea in 42.4% and vomiting in 25.3%.[7]
  • Dehydration and kidney injury. Tirzepatide’s label warns that vomiting and diarrhea can lead to acute kidney injury.[9]
  • Low blood pressure. In TRIUMPH-2, hypotension affected up to 6% on retatrutide versus under 1% on placebo.[8]
  • Doubling up on GLP-1 drugs. The Zepbound and Wegovy labels both say not to combine them with other GLP-1 receptor agonists.[9][10] CagriSema contains semaglutide, so pairing it with retatrutide or tirzepatide would stack two GLP-1 drugs.
  • Unknown products. FDA says cagrilintide and retatrutide cannot be compounded and that products sold “for research purposes” are of unknown quality.[1] Researchers studying people who use unapproved retatrutide noted that “peptide stacking” with other unapproved peptides may explain some of the symptoms they report.[16]

For a broader look at combining retatrutide with other drugs, see retatrutide stacks.

“Cagrilintide dosage with retatrutide”

There is no studied dose for this combination. Trial doses for cagrilintide alone and in CagriSema are in our cagrilintide dosage guide, and its side effects in cagrilintide side effects. Applying either drug’s trial dose to a combination would not be supported by any evidence.

What to ask a clinician

  • Is an approved medicine, used alone, enough for my goals?
  • If I plateau on tirzepatide or semaglutide, what are the evidence-based next steps?
  • Could I join a trial of an amylin drug alongside an incretin?

For how the two leading next-generation drugs compare on their own, see CagriSema vs retatrutide, our CagriSema guide, GLP-1 drugs compared and the GLP-1 drugs hub.